Search Results - "LALLA, EFTHALIA"

Abstract P2-09-10: Different CNVs account for 10.4% of pathogenic variants in 1418 patients referred for hereditary breast cancer testing by Tsoulos, Nikolaos, Agiannitopoulos, Konstantinos, Pepe, Georgia, Papadopoulou, Eirini, Tsaousis, Georgios N, Apostolopoulou, Despina, Meintani, Angeliki, Venizelos, Vassileios, Markopoulos, Christos, Iosifidou, Rodoniki, Karageorgopoulou, Sofia, Christodoulou, Christos, Natsiopoulos, Ioannis, Papazisis, Konstantinos, Vasilaki-Antonatou, Maria, Kabletsas, Eleftherios, Psyrri, Amanta, Giassas, Stylianos, Ziogas, Dimitrios, Lalla, Efthalia, Koumarianou, Anna, Papadimitriou, Christos, Ozmen, Vahit, Tansan, Sualp, Kaban, Kerim, Ozatlı, Tahsin, Eniu, Dan Tudor, Chiorean, Angelica, Blidaru, Alexandru, Nasioulas, George

“…Abstract Background: Breast cancer is the most frequently diagnosed cancer in women and about 10% of breast cancer cases are hereditary. BRCA1 and BRCA2 are…”
Get full text

Copy Number Variations (CNVs) Account for 10.8% of Pathogenic Variants in Patients Referred for Hereditary Cancer Testing by AGIANNITOPOULOS, KONSTANTINOS, PEPE, GEORGIA, TSAOUSIS, GEORGIOS N., POTSKA, KEVISA, BOUZARELOU, DIMITRA, KATSELI, ANASTASIA, NTOGKA, CHRISTINA, MEINTANI, ANGELIKI, TSOULOS, NIKOLAOS, GIASSAS, STYLIANOS, VENIZELOS, VASSILEIOS, MARKOPOULOS, CHRISTOS, IOSIFIDOU, RODONIKI, KARAGEORGOPOULOU, SOFIA, CHRISTODOULOU, CHRISTOS, NATSIOPOULOS, IOANNIS, PAPAZISIS, KONSTANTINOS, VASILAKI-ANTONATOU, MARIA, KABLETSAS, ELEFTHERIOS, PSYRRI, AMANTA, ZIOGAS, DIMITRIOS, LALLA, EFTHALIA, KOUMARIANOU, ANNA, ANASTASAKOU, KORNILIA, PAPADIMITRIOU, CHRISTOS, OZMEN, VAHIT, TANSAN, SUALP, KABAN, KERIM, OZATLI, TAHSIN, ENIU, DAN TUDOR, CHIOREAN, ANGELICA, BLIDARU, ALEXANDRU, RINSMA, MARRIT, PAPADOPOULOU, EIRINI, NASIOULAS, GEORGE

“…Background/Aim: Germline copy number variation (CNV) is a type of genetic variant that predisposes significantly to inherited cancers. Today, next-generation…”
Get full text

Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group by Fountzilas, Elena, Koliou, Georgia-Angeliki, Vozikis, Athanassios, Rapti, Vassiliki, Nikolakopoulos, Achilleas, Boutis, Anastasios, Christopoulou, Athina, Kontogiorgos, Ioannis, Karageorgopoulou, Sofia, Lalla, Efthalia, Tryfonopoulos, Dimitrios, Boukovinas, Ioannis, Rapti, Cleopatra, Nikolaidi, Adamantia, Karteri, Sofia, Moirogiorgou, Evangelia, Binas, Ioannis, Mauri, Davide, Aravantinos, Gerasimos, Zagouri, Flora, Saridaki, Zacharenia, Psyrri, Amanda, Bafaloukos, Dimitrios, Koumarianou, Anna, Res, Eleni, Linardou, Helena, Mountzios, Giannis, Razis, Evangelia, Fountzilas, George, Koumakis, Georgios

“…BackgroundWe evaluated real-world clinical outcomes and toxicity data and assessed treatment-related costs in patients with advanced breast cancer who received…”
Get full text

An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor by Res, Eleni, Lampaki, Sofia, Kontogiorgos, Loannis, Linardou, Helena, Christopoulou, Athina, Lalla, Efthalia, Spyratos, Dionisios, Bafaloukos, Dimitrios, Fountzilas, George, Koliou, Georgia-Angeliki, Grivas, Anastasios, Rigakos, Georgios, Papantoniou, Panagiotis, Pastelli, Nicoleta, Koufaki, Margarita-loanna, Aravantinos, Gerasimos, Mountzios, Giannis, Boutis, Anastasios, Vozikis, Athanassios, Koumarianou, Anna, Papakotoulas, Pavlos, Oikonomopoulos, Georgios

“…Purpose: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred first-line option for patients with advanced, EGFR-mutant…”
Get full text

An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece by Mountzios, Giannis, Lampaki, Sofia, Koliou, Georgia-Angeliki, Vozikis, Athanassios, Kontogiorgos, Ioannis, Papantoniou, Panagiotis, Koufaki, Margarita-Ioanna, Res, Eleni, Boutis, Anastasios, Christopoulou, Athina, Pastelli, Nicoleta, Grivas, Anastasios, Aravantinos, Gerasimos, Lalla, Efthalia, Oikonomopoulos, Georgios, Koumarianou, Anna, Spyratos, Dionisios, Bafaloukos, Dimitrios, Rigakos, Georgios, Papakotoulas, Pavlos, Fountzilas, George, Linardou, Helena

“…Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred first-line option for patients with advanced, EGFR-mutant non-small…”
Get full text

Prognostic Significance of Low HER2 Expression in Patients With Metastatic Hormone Receptor-positive Breast Cancer Treated With First Line CDK4/6 Inhibitors: A Greek Multicenter Real-world Data Analysis by DOUGANIOTIS, GEORGE, KESISIS, GEORGE, LALLA, EFTHALIA, KORANTZIS, IPPOKRATIS, BOUKOVINAS, IOANNIS, PAPAZISIS, KONSTANTINOS

“…Background/Aim: Low expression of HER2 has defined a new “HER2-low” subgroup of breast cancer with distinct clinicopathological characteristics and both…”
Get full text